Responses
Clinical and epidemiological research
Extended report
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
Compose a Response to This Article
Other responses
No responses have been published for this article.